U.S. markets close in 5 hours 47 minutes

HUTCHMED (China) Limited (HCM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.32+0.25 (+1.78%)
As of 10:11AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close14.07
Bid14.34 x 1300
Ask14.46 x 3000
Day's Range14.18 - 14.86
52 Week Range8.40 - 43.94
Avg. Volume680,691
Market Cap2.476B
Beta (5Y Monthly)0.50
PE Ratio (TTM)N/A
EPS (TTM)-1.23
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.86
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for HCM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • HUTCHMED (China) Limited
    Daily – Vickers Top Buyers & Sellers for 06/23/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    14 days agoArgus Research
View more
  • GlobeNewswire

    Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007

    SAN DIEGO and SHANGHAI and HONG KONG and SYDNEY, Australia, July 06, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announce today that the first participant, based in Australia, was dosed in a global Phase I trial of IMG-007, an investigational OX40 antagonistic monoclonal antibody. The Phase I study is a multi-stage, double-blind, randomized, placebo-controlled, dose-escalation study in healthy volunteers,

  • GlobeNewswire

    HUTCHMED to Announce 2022 Half-Year Financial Results

    HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2022 on Monday, August 1, 2022 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED managemen

  • GlobeNewswire

    HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China

    HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that TAZVERIK® (tazemetostat) has been approved by the Health Commission and Medical Products Administration of Hainan Province to be used in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (“Hainan Pilot Zone”), under the Clinically Urgently Needed Imported Drugs scheme, for the treatment of certain patients wi